Journal: Nature Communications

Article Title: Targeting QKI-7 in vivo restores endothelial cell function in diabetes

doi: 10.1038/s41467-020-17468-y

Figure Lengend Snippet: Morphology of hiPSCs and their EC differentiated counterparts are shown by bright field microscopy. Scale bar: 50 μm ( a ). Flow cytometry showed the pure population of hiPS-derived ECs after MACS selection using CD144 magnetic beads ( b ). Immunofluorescence confocal image showing that the differentiated ECs expressed the EC-specific markers CD31, CD144, and ZO-1 localizing to cell–cell junction. QKI-7 displayed perinuclear cytoplasm localization. Scale bar: 25 μm ( c ). The expression of EC marker proteins CD31, CD144, KDR, and eNOS was shown by western blot ( d ). hiPS-ECs formed tube structure indicating their angiogenic capacity. Scale bar: 200 μm ( e ). Data are from n = 3 representative images. Source data are provided as a Source data file.

Article Snippet: Primary antibodies include QKI-7 (UC Davis/NIH NeuroMab Facility 73-200, WB 1:1000, ICC 1:100), CD144 (St John’s Laboratory STJ96234, WB 1:1000, ICC 1:200), CD31 (Abcam AB28364, WB 1:1000, ICC 1:20), KDR (R&D Systems MAB3571, WB 1:1000), FLK1 (Thermo Fisher Scientific MA5-15157, WB 1:1000), eNOS (Abcam AB76198, WB 1:1000), NLGN1 (Abcam ab153821, WB 1:1000), β-actin (R&D Systems MAB8928, WB 1:1000), and ZO-1 (Thermo Fisher Scientific 40-2200, ICC 1:200).

Techniques: Microscopy, Flow Cytometry, Derivative Assay, Selection, Magnetic Beads, Immunofluorescence, Expressing, Marker, Western Blot

Journal: Translational oncology

Article Title: Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.

doi: 10.1016/j.tranon.2024.102108

Figure Lengend Snippet: Fig. 4. CHI3L1 is auto-induced in cells with WT and mutant EGFR. NHBE, A549, H1975 and HCC827 cells were incubated in the presence and absence of rCHI3L1 and the levels of mRNA encoding CHI3L1 and CHI3L1 protein accumulation were evaluated. The levels of mRNA encoding CHI3L1 were evaluated using qRT-PCR as illustrated in panel A. The levels of CHI3L1 protein accumulation can be seen in the Western blot evaluations and immunocytochemistry in panel B and C. The values in panel A represent the mean ± SEM of at least triplicate evaluations. The values in panels B and C are representative of at least 3 similar evaluations. (*p < 0.05 by t-test). Scale bar=25μm, it applies to every subpanel of Panel C.

Article Snippet: The primary antibodies used in this study are anti-(a) human CHI3L1 (R&D Systems, MN, US, #AF2599-SP) and anti-KEAP-1(Santa Cruz Biotechnology, TX, US, #8047), β-actin (Santa Cruz Biotechnology, TX, US, # Sc47778) antibodies.

Techniques: Mutagenesis, Incubation, Quantitative RT-PCR, Western Blot, Immunocytochemistry

Journal: Translational oncology

Article Title: Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.

doi: 10.1016/j.tranon.2024.102108

Figure Lengend Snippet: Fig. 6. Effects of CHI3L1 inhibitors and TKI, alone and in combination, on the EGFR axis in vitro. HCC827 cells were incubated with rCHI3L1 and the effects of osimertinib (OSM) and FRG on the expression of CHI3L1, EGF and EGFR were evaluated by qRT-PCR (panels A–C). In panels D and E, H1975 cells were incubated with low doses of osimertinib (OSM) and FRG, alone or in combination, and the levels of mRNA encoding CHI3L1 and EGF were evaluated. In panel F, H1975 cells were incubated with osimertinib (OSM) and FRG antibody, alone or in combination, and the levels of apoptosis were evaluated by TUNEL staining. (*p < 0.05; **p < 0.01; *** p < 0.001, ****p < 0.0001 by ANOVA with multiple comparisons). ns, not significant.

Article Snippet: The primary antibodies used in this study are anti-(a) human CHI3L1 (R&D Systems, MN, US, #AF2599-SP) and anti-KEAP-1(Santa Cruz Biotechnology, TX, US, #8047), β-actin (Santa Cruz Biotechnology, TX, US, # Sc47778) antibodies.

Techniques: In Vitro, Incubation, Expressing, Quantitative RT-PCR, TUNEL Assay, Staining

Journal: Translational oncology

Article Title: Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.

doi: 10.1016/j.tranon.2024.102108

Figure Lengend Snippet: Fig. 8. Anti-CHI3L1 and TKI interact to inhibit tumor metastasis. WT mice were challenged with B16-F10 (B16) melanoma cells or control vehicle and treated with control IgG, FRG and or TKIs, alone or in combination. Melanoma lung metastasis was evaluated 2 weeks later. (A) Representative lungs from mice treated with control IgG, FRG and or gefitinib, alone or in combination. (B) The number of pleural melanoma colonies was quantitated in the lungs from the mice in panel A. (C) Representative lungs from mice treated with IgG, FRG and osimertinib, alone and in combination. (D) The number of pleural melanoma colonies was quantitated in the lungs from the mice in panel C. In panels B and D, each dot is representative of an individual animal. Panels A and C are representative of at least 3 evaluations. The values in panels B and D represent the mean ± SEM of the evaluations represented by the individual dots in the lungs from the experiments illustrated in panel A and C respectively. *P < 0.05. ***P < 0.001; ****P < 0.0001. by ANOVA with multiple comparisons). ns, not significant.

Article Snippet: The primary antibodies used in this study are anti-(a) human CHI3L1 (R&D Systems, MN, US, #AF2599-SP) and anti-KEAP-1(Santa Cruz Biotechnology, TX, US, #8047), β-actin (Santa Cruz Biotechnology, TX, US, # Sc47778) antibodies.

Techniques: Control